미국 · 보도자료 · Tectonic Therapeutic · 2026-09-29 12:00
TX2100, 모세혈관확장증 치료 임상 1상서 안전성·PK 입증
WATERTOWN, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic” or the “Company”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced favorable topline results from its Phase 1a clinical trial evaluating TX
Tectonic Therapeutic 다른 공시·급등 이유 보기 · GK의 공시레이더 — 미국·한국 실시간 공시
